Latano-Vision Sine (Latanoprost)

Latanoprost binds to FP receptors in the ciliary body, promoting remodeling of the extracellular matrix and increasing uveoscleral outflow of aqueous humor. This enhanced drainage lowers intraocular pressure, which is the primary therapeutic goal in glaucoma management.

The dosing regimen is determined by the prescribing clinician. Typically, one drop is instilled into each affected eye once daily, usually in the evening, but the exact schedule and duration are set by the treating eye‑care professional.

Safety data for latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong IOP‑lowering efficacy. Compared with alternatives such as bimatoprost or travoprost, latanoprost has a similar efficacy profile but may differ slightly in side‑effect patterns, such as the degree of iris pigmentation change.

Store the ophthalmic solution at or below 25 °C, protected from light and moisture. Keep the bottle tightly closed in its original packaging, avoid freezing, and discard any product that appears discolored or contaminated.

Instill one drop into the conjunctival sac of each prescribed eye, preferably in the evening. Avoid touching the tip of the bottle to the eye or any surface, and wash hands before and after application to maintain sterility.

Serious adverse events, although rare, include severe ocular inflammation (uveitis), allergic reactions, macular edema, and a paradoxical rise in intraocular pressure. Patients should seek immediate medical attention if they experience sudden vision changes, eye pain, or signs of infection.

Individuals with known hypersensitivity to latanoprost or any excipients, as well as those with active ocular infections, severe inflammation, or recent ocular surgery, should avoid using this medication unless directed otherwise by their eye‑care specialist.